欢迎访问《现代生物医学进展》编辑部！

近年来,糖尿病肺部病变越来越受到关注。研究发现糖尿病患者存在肺通气功能障碍、弥散功能障碍,易于发生肺纤维化、合并感染等。这主要与糖尿病时炎症介质的参与，ACE 基因存在插入多态性，氧化应激损伤和抗氧化失衡等有关。目前研究发现血管紧张素转换酶抑制剂（ACEI）/ 血管紧张素受体阻滞剂(ARB)对糖尿病肺炎、慢性阻塞性肺疾病、肺间质纤维化等肺损伤有保护作用，这可能与ACEI具有调节免疫反应、减轻细胞因子水平、抗氧化应激损伤等机制有关。

英文摘要:

In recent years, more and more attention to diabetes lung lesions. The study found that people with diabetes exist pulmonary ventilation function barrier, the dispersion function obstacle, are more prone to pulmonary fibrosis, amalgamative infection, etc. This is mainly related to diabetes mediators of inflammation participation, ACE gene exists insert polymorphism, oxidative stress damage and antioxidant imbalance and so on. The present study found that angiotensin converting enzyme inhibitors (ACEI) / angiotensin receptor blockers (ARB) to diabetes pneumonia, chronic obstructive pulmonary disease, pulmonary interstitial fibrosis and other lung injury have protective effect, this could be related with ACEI which can adjust the immune reaction, reduce cell factor level, antioxidant stress damage, and other relevant mechanism.

View Full Text View/Add Comment Download reader